# Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

> **NCT00079833** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 25 (—)

## Conditions studied

- Zollinger-Ellison Syndrome

## Interventions

- **DRUG:** Esomeprazole magnesium (Nexium)

## Key facts

- **NCT ID:** NCT00079833
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 25 (—)
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079833, "Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00079833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*